Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing human enzyme therapeutics for patients with rare genetic and cancer-related diseases. The company's primary product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing Phase III trials to assess its safety and efficacy in treating Arginase 1 deficiency. Aeglea's preclinical pipeline includes several innovative candidates, such as ACN00177 for homocystinuria, AEB5100 which degrades plasma cystine and cysteine, AEB2109 targeting the degradation of methionine, and AEB3103. Founded in 2013, Aeglea BioTherapeutics aims to address unmet medical needs in the field of rare metabolic disorders through its specialized enzyme therapies.

Armen Shanafelt

Director

1 past transactions

Spyre Therapeutics

Acquisition in 2023
Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.